Show simple item record

dc.contributor.authorBoum, Y
dc.contributor.authorJuan-Giner, A
dc.contributor.authorHitchings, M
dc.contributor.authorSoumah, A
dc.contributor.authorStrecker, T
dc.contributor.authorSadjo, M
dc.contributor.authorCuthbertson, H
dc.contributor.authorHayes, P
dc.contributor.authorTchaton, M
dc.contributor.authorJemmy, JP
dc.contributor.authorClarck, C
dc.contributor.authorKing, D
dc.contributor.authorFaga, EM
dc.contributor.authorBecker, S
dc.contributor.authorHalis, B
dc.contributor.authorGunnstein, N
dc.contributor.authorCarroll, M
dc.contributor.authorRøttingen, JA
dc.contributor.authorKondé, MK
dc.contributor.authorDoumbia, M
dc.contributor.authorHenao-Restrepo, AM
dc.contributor.authorKieny, MP
dc.contributor.authorCisse, M
dc.contributor.authorDraguez, B
dc.contributor.authorGrais, RFF
dc.date.accessioned2020-07-26T00:21:59Z
dc.date.available2020-07-26T00:21:59Z
dc.date.issued2020-06-26
dc.date.submitted2020-07-25
dc.identifier.pmid32499066
dc.identifier.doi10.1016/j.vaccine.2020.04.066
dc.identifier.urihttp://hdl.handle.net/10144/619707
dc.description.abstractBackground As part of a Phase III trial with the Ebola vaccine rVSVΔG-ZEBOV-GP in Guinea, we invited frontline workers (FLWs) to participate in a sub-study to provide additional information on the immunogenicity of the vaccine. Methods We conducted an open‐label, non‐randomized, single-arm immunogenicity evaluation of one dose of rVSVΔG-ZEBOV-GP among healthy FLWs in Guinea. FLWs who refused vaccination were offered to participate as a control group. We followed participants for 84 days with a subset followed-up for 180 days. The primary endpoint was immune response, as measured by ELISA for ZEBOV-glycoprotein–specific antibodies (ELISA-GP) at 28 days. We also conducted neutralization, whole virion ELISA and enzyme-linked immunospot (ELISPOT) assay for cellular response. Results A total of 1172 participants received one dose of vaccine and were followed-up for 84 days, among them 114 participants were followed-up for 180 days. Additionally, 99 participants were included in the control group and followed up for 180 days. Overall, 86.4% (95% CI 84.1–88.4) of vaccinated participants seroresponded at 28 days post-vaccination (ELISA- GP) with 65% of these seroresponding at 14 days post-vaccination. Among those who seroresponded at 28 days, 90.7% (95% CI 82.0–95.4) were still seropositive at 180 days. The proportion of seropositivity in the unvaccinated group was 0.0% (95% CI 0.0–3.8) at 28 days and 5.4% (95% CI 2.1–13.1) at 180 days post-vaccination. We found weak correlation between ELISA-GP and neutralization at baseline but significant pairwise correlation at 28 days post-vaccination. Among samples analysed for cellular response, only 1 (2.2%) exhibited responses towards the Zaire Ebola glycoprotein (Ebola GP ≥ 10) at baseline, 10 (13.5%) at day 28 post-vaccination and 27 (48.2%) at Day 180. Conclusions We found one dose of rVSVΔG-ZEBOV-GP to be highly immunogenic at 28- and 180-days post vaccination among frontline workers in Guinea. We also found a cellular response that increased with time.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.rightsWith thanks to Elsevier.en_US
dc.subjectCellular response
dc.subjectEbola vaccine
dc.subjectFrontline workers
dc.subjectHumoral response
dc.subjectImmunogenicity
dc.titleHumoral and cellular immune response induced by rVSVΔG-ZEBOV-GP vaccine among frontline workers during the 2013-2016 West Africa Ebola outbreak in Guineaen_US
dc.typeArticle
dc.identifier.eissn1873-2518
dc.identifier.journalVaccineen_US
dc.source.journaltitleVaccine
dc.source.volume38
dc.source.issue31
dc.source.beginpage4877
dc.source.endpage4884
refterms.dateFOA2020-07-26T00:22:00Z
dc.source.countryUnited Kingdom
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Boum et al 2020 Humoral and ...
Size:
1.162Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record